SCHEMBL22609200

SCHEMBL22609200

CCOC(=O)c1nsc(C)c1Br

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.44
▸ TSHR P16473 2/20 0.43
▸ ALDH1A1 P00352 5/20 0.42
▸ CYP1A2 P05177 2/20 0.42
▸ KDM4E B2RXH2 5/20 0.41
▸ LMNA P02545 2/20 0.41
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ TARBP2 Q15633 1/20 0.39
▸ FHIT P49789 1/20 0.39
▸ ILK Q13418 1/20 0.38
▸ MAPT P10636 6/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ MAPK1 P28482 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ DHODH Q02127 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23596009 0.80 RAB9A (0.49) TSHRALDH1A1KDM4ELMNAMEN1
SCHEMBL26101362 0.79 KDM4E (0.44) GAATSHRALDH1A1CYP1A2KDM4E
SCHEMBL22609240 0.79 ALDH1A1 (0.50) GAATSHRALDH1A1CYP1A2KDM4E
SCHEMBL4699036 0.77 TSHR (0.42) GAATSHRALDH1A1CYP1A2KDM4E
SCHEMBL27042943 0.75 MAPT (0.40) GAATSHRALDH1A1CYP1A2KDM4E
SCHEMBL22609216 0.73 GAA (0.44) GAATSHRALDH1A1CYP1A2KDM4E
SCHEMBL299269 0.73 GAA (0.56) GAAALDH1A1CYP1A2KDM4ELMNA
SCHEMBL16986060 0.73 HPGD (0.47) GAATSHRALDH1A1CYP1A2KDM4E
SCHEMBL22609226 0.73 MAPT (0.56) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL20027965 0.71 TSHR (0.58) GAATSHRALDH1A1CYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed
EP-3731840-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF Orfan Biotech Inc. (US) 2020-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS GAA 129/4885TSHR 1767/4885ALDH1A1 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback